In addition, in a report of six cases of patients with PWS and T2D never treated with GH, the treatment with 1.2 to 1.8 mg/day of liraglutide, a long-acting GLP-1R agonists, or 20 mg/day of exenatide for two years, a trend to reduced HbA1c and mean blood glucose, BMI, and waist circumference [23]. The gene discussed is GLP1R; the disease is Prader-Willi syndrome.